NIH Grant Award

Spring Bank Pharmaceuticals Awarded NIH Grant for
Hepatitis Program 
  
  
Company's innovative Small Molecule Nucleic Acid Hybrid for the
discovery and development of a novel class of therapeutics for the 
treatment Hepatitis B and C receives support from the National Institute
of Health 
 
Milford, Ma., July 1, 2009‐‐Spring Bank Pharmaceuticals announced today that it has
received a Small Business Innovation Research (SBIR)  Phase I grant from the National
Institute  of Health  (NIH). The NIH grant award is $600,000 covering the two year
period from July 2009 through June 2011 and has been awarded to support the
Company's program for the discovery and development of novel therapeutics for the
treatment of Hepatitis B and Hepatitis C infections. Upon completion of this SBIR Phase I
grant, Spring Bank will be eligible to apply for continuing support through a SBIR
Phase II grant. 
 
"It is clear that the NIH is highly motivated to fund novel approaches to tackling the
serious  healthcare burden of Hepatitis B and C.  We believe that this SBIR grant award
demonstrates  their strong support for our program to develop an important new class
of pharmaceuticals  for the treatment of Hepatitis B and C.”  said Kris Iyer, Ph.D., Chief
Scientific Officer of Spring Bank Pharmaceuticals.  
 
The project described was supported by Award Number R43AI084186 from the National
Institute of Allergy and Infectious Diseases.  The content is solely the responsibility of
the authors and does not necessarily represent the official views of the National
Institute of Allergy and Infectious Diseases of the National Institutes of Health. 
 
About the Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is an IND-stage drug discovery company.  Based on our proprietary
platform technology, we are developing a pipeline of products representing a new class of
pharmaceuticals we call small molecule nucleic acid hybrids “SMNH” with a wide range of
applications and multi-billion doll ar market potential.

About Hepatitis

Over 350 million people are chronically infected with HBV virus worldwide. The HBV virus is a DNA virus which incorporates into the hepatocyte DNA. Read More >>

Approximately 170 million people worldwide and 4 million in the United States are infected with HCV. HCV infection is one of the most significant public health threats facing Americans.
Read More >>